Benjamin A. Auspitz

Founder & Chairman at Dimension Therapeutics, Inc.

Benjamin A. Auspitz

Benjamin A. Auspitz

Founder & Chairman at Dimension Therapeutics, Inc.

Overview
Career Highlights

Dimension Therapeutics, Inc.

RelSci Relationships

1551

Number of Boards

15

Birthday

1973

Age

47

Contact Data
Trying to get in touch with Benjamin A. Auspitz? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Relationships
RelSci Relationships are individuals Benjamin A. Auspitz likely has professional access to. A relationship does not necessarily indicate a personal connection.

Partner at OrbiMed Advisors LLC

Relationship likelihood: Strong

Executive Partner at F-Prime Capital Partners

Relationship likelihood: Strong

General Counsel & Executive Vice President at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Strong

Former Chief Executive Officer at Symbiomix Therapeutics LLC

Relationship likelihood: Strong

President & Managing Partner at F-Prime Capital Partners

Relationship likelihood: Strong

Co-Founder at Dimension Therapeutics, Inc.

Relationship likelihood: Strong

Chief Business Officer & Executive Vice President at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Strong

Co-Founder at Audentes Therapeutics, Inc.

Relationship likelihood: Strong

Chairman at Compass Therapeutics LLC

Relationship likelihood: Strong

Scientific Founder at Turnstone Biologics, Inc.

Relationship likelihood: Strong

Paths to Benjamin A. Auspitz
Potential Connections via
Relationship Science
You
Benjamin A. Auspitz
Founder & Chairman at Dimension Therapeutics, Inc.
Education
B.A.

The oldest corporation in the Western Hemisphere is the Harvard Corporation, known formally as the President and Fellows of Harvard College. It is the smaller of Harvard’s two governing boards; the other is the Board of Overseers. Following are the members of the Harvard Corporation.

Career History
Partner
2005 - ?

Impresa focuses on early-stage investments in start-up companies across US and International portfolio companies. There fund focuses on companies operating in the fields of biopharmaceutical, medical technology & healthcare IT and services.There funds are larger and more global. In the US and Europe, they are F-Prime Capital investing in healthcare (formerly Fidelity Biosciences) and in technology (formerly part of Devonshire Investors). In other geographies, there sister fund is called Eight Roads (formerly Fidelity Growth Partners), with investment teams in London, Shanghai, Beijing, Hong Kong, Tokyo, and Mumbai with over $2 trillion in assets under management.

Director for Corporate Strategy
Prior

CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA

Consultant
1999 - 2000

Braun Consulting, Inc. is a professional services firm delivering customer-focused business solutions to companies. Braun Consulting combines cutting-edge business intelligence and CRM/eCRM technologies with business strategy. Founded in 1993, Chicago-based Braun Consulting has five offices throughout the U.S. . The service includes integrates business intelligence, Internet application development skills and customer relationship management technologies with business strategy

Boards & Committees
Director
Current

Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA.

Director
Current

Compass Therapeutics LLC operates as a healthcare industry focusing on biotechnology. The firm discovers and develops antibodies used in drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals and engineered protein constructs. The company was founded by Errik B. Anderson and Thomas J. Schuetz in 2014 and is headquartered in Cambridge, MA.

Member, Board of Directors
Current

Indalo Therapeutics, Inc. operates as a biopharmaceutical firm that develops integrin antagonists for patients suffering from serious fibrotic diseases such as nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF). The company was founded by David Griggs, Williamson Z. Bradford III, Peter Ruminski, and Robert W. Karr and is headquartered in Cambridge, MA.

Political Donations
$1,300
2007
$200
2006

Former Senator from Connecticut

Investments
Details Hidden

Dimension Therapeutics, Inc. engages in the provision of medical development. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. The company was founded by Ben Auspitz on October 2013, and is headquartered in Cambridge, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Benjamin A. Auspitz. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Benjamin A. Auspitz's profile does not indicate a business or promotional relationship of any kind between RelSci and Benjamin A. Auspitz.